Effects of direct hemoperfusion with a beta2-microglobulin adsorption column on hypercytokinemia in rats.
OBJECTIVE
Blood purification therapies have been clinically applied to treat the cytokine-induced pathological responses. The effects of direct hemoperfusion(DHP) with a beta(2)-microglobulin (BMG) adsorption column on hypercytokinemia were investigated.


METHODS
A hypercytokinemia model was prepared by injecting lipopolysaccharide (LPS) into femoral veins of male Wistar rats weighing 250-400 g. The hypercytokinemic rats were connected to the DHP system using a small BMG adsorption column, and time course changes in plasma levels of inflammatory cytokines were then examined.


RESULTS
Plasma levels of interleukins (IL) 1beta and 6 and tumor necrosis factor alpha (TNF-alpha) were found to be significantly elevated within 3 h after LPS injection in the control group that underwent extracorporeal circulation without the BMG adsorption column, whereas the increases in plasma levels of IL-6 and TNF-alpha were significantly inhibited in the group that was treated with the BMG adsorption column. The adsorption rates of cytokines with the BMG adsorption column were 20-40% for IL-1beta and IL-6 and 10-85% for TNF-alpha during treatment for 3 h.


CONCLUSIONS
These results suggest that the systemic inflammatory response syndrome with hypercytokinemia might be treated with DHP using the BMG adsorption column.
Nakatani
Tatsuya
T
Department of Urology and Division of Artificial Kidney, Osaka City University Medical School, Osaka, Japan. nakatani@misc.med.osaka-cu.ac.jp
Tsuchida
Kenji
K
Fu
Ontaku
O
Sugimura
Kazunobu
K
Takemoto
Yoshiaki
Y
D000327:Adsorption; D000818:Animals; D002853:Chromatography, Liquid; D019446:Endotoxemia / Q000097:blood / Q000139:chemically induced / Q000628:therapy; D006464:Hemoperfusion / Q000295:instrumentation; D015850:Interleukin-6 / Q000097:blood*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D001613:beta 2-Microglobulin
D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D001613:beta 2-Microglobulin